There Is a Newer Version
of
this Subtitle
2020 Maryland Statutes
Health - General
Title 21 - Food, Drugs, and Cosmetics
Subtitle 2C - Prescription Drug Affordability Board
- Section 21-2C-01 - Definitions
- Section 21-2C-02 - Prescription Drug Affordability Board
- Section 21-2C-03 - Membership
- Section 21-2C-04 - Prescription Drug Affordability Stakeholder Council
- Section 21-2C-05 - Disclosure of Conflicts of Interest
- Section 21-2C-06 - Acceptance of Gratuities Prohibited
- Section 21-2C-07 - Study and Report -- Pharmaceutical Distribution and Payment System in State; Policy Options Used in Other States and Countries
- Section 21-2C-08 - Collection, Review, and Use of Transparency Data for Prescription Drug Products
- Section 21-2C-09 - Cost Review of Prescription Drug Products With Affordability Challenges
- Section 21-2C-10 - Confidentiality
- Section 21-2C-11 - Funding Source
- Section 21-2C-12 - Enforcement
- Section 21-2C-13 - Drafting Action Plan for Implementing Process to Set Upper Payment Limits for Prescription Drug Products [Section Subject to Abrogation]
- Section 21-2C-14 - Setting Upper Payment Limits for Prescription Drug Products [Section Enacted Subject to Contingency]
- Section 21-2C-15 - Appeals of Board Decisions [Section Enacted Subject to Contingency]
- Section 21-2C-16 - Board and Stakeholder Council Report and Recommendation Concerning Upper Payment Limits [Section Enacted Subject to Contingency]
Disclaimer: These codes may not be the most recent version. Maryland may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.